Initial Therapy With Merck’ JANUMET To Provide Greater Blood Sugar Lowering

Merck has presented new data at the American Diabetes Association (ADA’) 69th Annual Scientific Sessions. It showed that initial treatment with JANUMET (sitagliptin/metformin) provided greater blood sugar improvements in drug naive patients with type 2 diabetes, as compared with metformin alone.

In separate post-hoc analysis, data pooled from 104 weeks of studies showed that JANUVIA (sitagliptin), when taken alone (two studies) or in combination with metformin (two studies), provided significant blood sugar lowering, which was sustained over two years.

Barry Goldstein, Vice President of Clinical Research, Diabetes and Obesity at Merck, said: In this study, initial combination therapy with the fixed-dose combination JANUMET for the treatment of type 2 diabetes helped patients achieve blood sugar goals more effectively than metformin alone. For physicians who treat patients who need to lower their blood sugar levels, this may be useful information.